Delivery Order SPE2DB20D1109-SPE2DB25FP54C
- Not listed
- The Defense Logistics Agency awarded a $16,119.77 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on July 30, 2025, with completion scheduled for July 31, 2025. This non-set-aside competitive award represents a single delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $6,217.49 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 mg tablets (30-count units) under a firm fixed-price contract type. The award was made on July 22, 2025, with an ultimate completion date of July 23, 2025, and represents a non-competitive set-aside delivery against an existing indefinite delivery contract. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units. This firm fixed price delivery order, valued at $8,141.67, represents a non-competitive set-aside procurement and is scheduled for ultimate completion by August 1, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This...
- The Defense Logistics Agency awarded a $20,369.56 delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count packaging) on July 28, 2025, with an ultimate completion date of July 29, 2025. This non-set-aside, competitively awarded contract employs firm fixed-price terms and represents a child delivery order under AmerisourceBergen's larger contract vehicle. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $1,599.24 to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of XELJANZ XR 11 MG tablets in quantities of 30 units. This firm fixed-price delivery order represents a non-set-aside competitive award and is scheduled for completion by July 22, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement....
- The Defense Logistics Agency awarded a $2,477.39 delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 MG tablets (30-count units) under a firm fixed price contract. This non-set-aside award, issued on August 1, 2025, with completion targeted for August 4, 2025, represents a routine pharmaceutical procurement supporting federal medical supply requirements. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for the Defense...
- The Defense Logistics Agency awarded a $3,796.45 delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on July 25, 2025, with an ultimate completion date of July 28, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be delivered to the company's corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $20,578.74 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) under a firm fixed-price contract type. The award was made on August 4, 2025, with an ultimate completion date of August 5, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, performed the work at its corporate office location and serves as a critical...
- The Defense Logistics Agency awarded a $36,826.65 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 5, 2025. This delivery order represents a single...
- The Defense Logistics Agency awarded a $4,343.52 firm fixed price delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on July 29, 2025, with completion targeted for July 30, 2025. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB25FP54CDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,874.93 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on August 7, 2025, with an ultimate completion date of August 8, 2025. This firm fixed-price delivery order was not set-aside and represents a competitive award under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's corporate headquarters location in Conshohocken, Pennsylvania. This delivery order is part of AmerisourceBergen's comprehensive pharmaceutical supply mission supporting federal military and veteran healthcare systems. As a major pharmaceutical distributor serving the federal government, AmerisourceBergen fulfills critical medical procurement requirements across multiple therapeutic categories through the DLA Medical Supply Chain. The underlying IDC serves as a global pharmaceutical support vehicle enabling the company to supply brand-name and generic medications, vaccines, and specialized medical supplies to support Defense Health Agency operations and other government healthcare systems worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.9k | 8/7/25 |